Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash & Equivalents (2022 - 2025)

Maravai Lifesciences Holdings (MRVI) has 4 years of Cash & Equivalents data on record, last reported at $243.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 57.87% year-over-year to $243.6 million; the TTM value through Sep 2025 reached $243.6 million, down 57.87%, while the annual FY2024 figure was $322.4 million, 43.93% down from the prior year.
  • Cash & Equivalents reached $243.6 million in Q3 2025 per MRVI's latest filing, down from $269.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $632.1 million in Q4 2022 and bottomed at $243.6 million in Q3 2025.
  • Average Cash & Equivalents over 4 years is $472.8 million, with a median of $573.2 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: decreased 0.25% in 2024, then crashed 57.87% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $632.1 million in 2022, then fell by 9.04% to $575.0 million in 2023, then crashed by 43.93% to $322.4 million in 2024, then decreased by 24.45% to $243.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $243.6 million in Q3 2025, $269.9 million in Q2 2025, and $285.1 million in Q1 2025.